TNFRSF8 and Hodgkins lymphoma: This includes a bispecific, tetravalent chimeric antibody construct, AFM13, specifically targets CD30 on Hodgkin’s lymphoma (HL) cells and recruits and activates NK cells by binding to CD16A.